FDA Approves Simtriyo (Centanafadine) for ADHD
Introduction
ADHD is a neurodevelopmental disorder that can affect individuals throughout childhood and adulthood. It is characterised by persistent difficulties with attention, impulse control and hyperactivity, which may interfere with everyday functioning. Common symptoms include difficulty concentrating, forgetfulness, disorganisation, restlessness and trouble completing tasks. These challenges can affect academic performance, relationships, social interactions and professional life (1).
ADHD management may include medication and psychosocial interventions, depending on the individual's age, symptom severity and clinical needs. There are two main types of medication used to treat ADHD: stimulants and non-stimulants. Stimulants, such as methylphenidate and amphetamines, are commonly prescribed and remain the mainstay of pharmacological treatment. Non-stimulant options include atomoxetine, guanfacine and clonidine, which may be considered in certain patients (1).
Despite the availability of established medications, treatment response and tolerability vary between individuals. Side effects and inadequate symptom control may limit their use in some patients, highlighting the need for additional pharmacological options (2). Simtriyo (centanafadine) introduces an additional pharmacological option for ADHD management through a distinct triple neurotransmitter reuptake inhibition mechanism (3).
How do existing ADHD medications work?
ADHD medications work by influencing chemical messengers in the brain, particularly dopamine and norepinephrine. These neurotransmitters play important roles in attention, working memory and impulse control. Alterations in their signalling are associated with difficulties in attention and self-regulation in individuals with ADHD (2).
Stimulants such as methylphenidate inhibit the reuptake of dopamine and norepinephrine, allowing these neurotransmitters to remain available in the synaptic space for longer. Amphetamines also increase the release of these neurotransmitters. Among non-stimulants, atomoxetine selectively increases the availability of norepinephrine (2). Other medications used in selected patients include bupropion and tricyclic antidepressants, as well as alpha-2 adrenergic agonists such as clonidine and guanfacine, which act through different mechanisms to help manage ADHD symptoms (1).
Why are new ADHD treatments needed?
Although existing ADHD medications are effective for many patients, they do not work equally well for everyone. Some individuals experience side effects such as reduced appetite, sleep disturbances and changes in blood pressure, while others may not respond adequately or may have difficulty tolerating treatment. Differences in age, symptoms, lifestyle and individual preferences also influence treatment needs. Newer medications and alternative treatment approaches aim to expand the available choices, improve treatment flexibility and help healthcare professionals tailor care to individual patients (2).
FDA approval of Simtriyo (Centanafadine)
On July 2026, the US Food and Drug Administration (FDA) approved Simtriyo (centanafadine) for the treatment of ADHD in adults and paediatric patients aged six years and older who weigh at least 20 kg. Centanafadine is the first approved norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) for ADHD, introducing a pharmacological approach that targets three neurotransmitter systems (3).
How does Simtriyo (Centanafadine) work?
Unlike many established ADHD medications that primarily target dopamine and norepinephrine, centanafadine acts on three neurotransmitter systems: norepinephrine, dopamine and serotonin (3). These chemical messengers are involved in regulating functions such as attention, alertness and mood (4).
Centanafadine works by blocking three proteins responsible for transporting these neurotransmitters back into nerve cells: the norepinephrine transporter (NET), dopamine transporter (DAT) and serotonin transporter (SERT). By slowing this reabsorption process, it allows these chemical messengers to remain available between nerve cells for longer. This triple reuptake activity distinguishes centanafadine from treatments that primarily target one or two neurotransmitter systems (3).
Unlike amphetamines, which also promote the release of neurotransmitters, centanafadine primarily acts by blocking their reuptake (3). However, although its activity on all three transporters has been demonstrated, the precise way in which this produces improvements in ADHD symptoms is not yet fully understood (5).
What does the clinical evidence show?
The FDA approval was supported by four randomised, double-blind, placebo-controlled clinical trials, including two studies in children and adolescents and two in adults. Each study lasted six weeks (5).
In children aged 6–12 years, treatment with the approved weight-based dose equivalent to 280 mg resulted in an average reduction of 16.3 points in ADHD symptom scores, compared with 10.8 points with placebo. Similarly, in adolescents aged 13–17 years, scores decreased by 18.5 points with the 280 mg dose, compared with 14.2 points with placebo (5).
The adult studies also demonstrated improvements. In the first study, symptom scores decreased by 10.1 points with the lower dose and 9.7 points with the higher dose, compared with 7 points with placebo. In the second study, the reductions were 12.1 and 12.5 points with the lower and higher doses, respectively, compared with 8.1 points with placebo (5).
In both adult studies, reductions in ADHD symptom scores were statistically significantly greater with centanafadine than with placebo. The adult trials used another formulation of centanafadine. The prescribing information states that no differences in effectiveness are expected between the low and high doses of that formulation and Simtriyo 210 mg and 280 mg once daily, respectively (5).
Dosage,Safety and Precautions
Simtriyo is available as an extended-release capsule in three strengths: 140 mg, 210 mg and 280 mg. The recommended dosage depends on the patient's age and, in younger children, their body weight (4).
Recommended daily dosage:
Children aged 6–12 years:
20 to less than 35 kg: 140 mg
35–50 kg: 210 mg
More than 50 kg: 280 mg
Adolescents aged 13–17 years:
280 mg once daily.
Adults:
Starting dose of 210 mg once daily, which may be increased to 280 mg depending on clinical response and tolerability.
The medication should be taken once daily in the morning, with or without food, preferably at approximately the same time each day. Capsules may be swallowed whole or opened and sprinkled over applesauce or yogurt, or mixed with orange juice. The contents should be consumed immediately, followed by water, without chewing the granules (5).
Common side effects include:
Children aged 6–12 years: Rash and decreased appetite.
Adolescents aged 13–17 years: Decreased appetite, nausea, rash, headache and abdominal pain.
Adults: Headache, decreased appetite, insomnia, nausea, dry mouth and diarrhoea (5).
Important safety precautions:
Suicidal thoughts and behaviours: Higher rates were reported in children aged 6-12 years receiving Simtriyo than in those receiving placebo. All paediatric patients should be closely monitored for changes in mood, behaviour or suicidal thoughts, clinical worsening or unusual changes in behaviour, particularly during the initial months of treatment (5).
Abuse and addiction: Simtriyo has the potential for misuse and addiction. Patients should be assessed for these risks before treatment and monitored throughout therapy. The medication should be stored securely (5).
Heart health: Simtriyo may increase blood pressure and heart rate. Patients should be assessed for existing heart conditions before starting treatment, with blood pressure and heart rate monitored during therapy. It should be avoided in patients with serious cardiac disease (5).
Growth in children: Long-term treatment may slow growth and cause weight loss. Height, weight and body mass index (BMI) should be monitored regularly (5).
Drug interactions: Simtriyo must not be taken with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping them because of the risk of serious drug interactions. Alcohol should be avoided while taking the medication and for at least two hours afterwards (5).
Frequently Asked Questions
1. What makes Simtriyo different from other ADHD medications?
Simtriyo (centanafadine) is the first FDA-approved ADHD medication that inhibits the reuptake of three neurotransmitters: norepinephrine, dopamine and serotonin. Most established ADHD medications primarily target one or two of these chemical messengers (3).
2. Is Simtriyo approved for children as well as adults?
Yes. The FDA approved Simtriyo for adults and children aged six years and older who weigh at least 20 kg (5).
3. Does Simtriyo cure ADHD?
ADHD currently has no known cure. However, treatments such as medication and behavioural interventions can help reduce symptoms and improve daily functioning.5 SIMTRIYO is one medication option for managing ADHD symptoms (5).
4. What are the common side effects of Simtriyo?
Common side effects vary by age group. They include decreased appetite and rash in younger children; nausea, headache and abdominal pain in adolescents; and headache, insomnia, nausea, dry mouth and diarrhoea in adults (5).
5. Can Simtriyo be taken with food?
Yes. Simtriyo can be taken once daily in the morning, with or without food. Capsules can be swallowed whole or opened and sprinkled over applesauce or yogurt, or mixed with orange juice, without chewing the granules (5).
Conclusion
The FDA approval of Simtriyo (centanafadine) introduces a new pharmacological option for ADHD, with a mechanism that targets three neurotransmitter systems: norepinephrine, dopamine and serotonin. Clinical trials have demonstrated improvements in ADHD symptoms in both adults and children, expanding the range of available treatment choices. However, its potential side effects and important safety warnings highlight the need for appropriate patient selection and regular monitoring. Although Simtriyo offers a different approach to ADHD management, further long-term evidence will help establish its safety and effectiveness over time. Ultimately, it represents another option that healthcare professionals can consider when individualising ADHD treatment.
About the Author
Dr. Geetika Gupta is a dentist, healthcare writer, and gold medalist who earned her Bachelor of Dental Surgery (BDS) degree from Rajiv Gandhi University of Health Sciences. With a keen interest in oral cancer, bone pathologies, and implantology, she is passionate about making complex medical information accessible and engaging for readers.
When she is not restoring smiles and caring for patients, Dr. Gupta channels her love for words into creating insightful, evidence-based content on a wide range of healthcare topics.
References:
Magnus W, Anilkumar AC, Shaban K. Attention Deficit Hyperactivity Disorder. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441838/
Baweja R, Faraone SV, Childress AC, Weiss MD, Loo SK, Wilens TE, Waxmonsky JG. From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. J Child Adolesc Psychopharmacol. 2024 May;34(4):167–182. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11302246/
Hu L. Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD). Med Chem Res. 2026 Sep;35(9):1548–1552. doi:10.1007/s00044-026-03612-8. Epub 2026 Aug 25. Available from: https://pubmed.ncbi.nlm.nih.gov/42640319/
Han J, Jiang C, Pruitt AA, Yu Y, Jiang J. Centanafadine (Simtriyo): a triple monoamine reuptake inhibitor for ADHD. Trends Pharmacol Sci. 2026 Oct;47(10):1186-1187. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC13591490/
US Food and Drug Administration. SIMTRIYO (centanafadine) extended-release capsules: Prescribing Information. Revised July 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218145s000lbl.pdf
National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder: What You Need to Know. Available from: https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in





Comments